References
- Liberal R, Longhi MS, Mieli-Vergani G, et al. Pathogenesis of autoimmune hepatitis. Best Prac Res Clin Gastroenterol. 2011;25(6):653–664. DOI:https://doi.org/10.1016/j.bpg.2011.09.009.
- Czaja AJ. Transitioning from idiopathic to explainable autoimmune hepatitis. Dig Dis Sci. 2015;60(10):2881–2900. DOI:https://doi.org/10.1007/s10620-015-3708-7.
- Floreani A, Restrepo-Jimenez P, Secchi MF, et al. Etiopathogenesis of autoimmune hepatitis. J Autoimmun. 2018;95:133–143.
- Mieli-Vergani G, Vergani D, Czaja AJ, et al. Autoimmune hepatitis. Nat Rev Dis Primers. 2018;4:18017.
- Czaja AJ. Examining pathogenic concepts of autoimmune hepatitis for cues to future investigations and interventions. World J Gastroenterol. 2019;25(45):6579–6606. DOI:https://doi.org/10.3748/wjg.v25.i45.6579.
- Chaouali M, Ben Azaiez M, Tezeghdenti A, et al. High levels of proinflammatory cytokines IL-6, IL-8, TNF-Alpha, IL-23, and IFN- in Tunisian patients with type 1 autoimmune hepatitis. Eur Cytokine Netw. 2020. DOI:https://doi.org/10.1684/ecn.2020.0450.
- Maggiore G, De Benedetti F, Massa M, et al. Circulating levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in children with autoimmune hepatitis. J Pediatr Gastroenterol Nutr. 1995;20(1):23–27. DOI:https://doi.org/10.1097/00005176-199501000-00005.
- Iwamoto S, Kido M, Aoki N, et al. TNF-alpha is essential in the induction of fatal autoimmune hepatitis in mice through upregulation of hepatic CCL20 expression. Clin Immunol. 2013;146:15–25.
- Akberova D, Kiassov AP, Abdulganieva D. Serum cytokine levels and their relation to clinical features in patients with autoimmune liver diseases. J Immunol Res. 2017;2017:9829436.
- Longhi MS, Ma Y, Bogdanos DP, et al. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol. 2004;41(1):31–37. DOI:https://doi.org/10.1016/j.jhep.2004.03.008.
- Liberal R, Grant CR, Holder BS, et al. In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression. Hepatology. 2015;62(3):863–875. DOI:https://doi.org/10.1002/hep.27884.
- Liberal R, Grant CR, Longhi MS, et al. Regulatory T cells: mechanisms of suppression and impairment in autoimmune liver disease. IUBMB Life. 2015;67(2):88–97. DOI:https://doi.org/10.1002/iub.1349.
- Longhi MS, Mieli-Vergani G, Vergani D. Regulatory T cells in autoimmune hepatitis: an updated overview. J Autoimmun. 2021;119:102619. DOI:https://doi.org/10.1016/j.jaut.2021.102619.
- Czaja AJ, Strettell MD, Thomson LJ, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology. 1997;25(2):317–323. DOI:https://doi.org/10.1002/hep.510250211.
- Czaja AJ, Carpenter HA, Santrach PJ, et al. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology. 1993;105(5):1502–1507. DOI:https://doi.org/10.1016/0016-5085(93)90157-8.
- van Gerven NM, de Boer YS, Zwiers A, et al. HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1. Genes Immun. 2015;16(4):247–252. DOI:https://doi.org/10.1038/gene.2014.82.
- Mann DA. Epigenetics in liver disease. Hepatology. 2014;60(4):1418–1425.
- Czaja AJ. Epigenetic changes and their implications in autoimmune hepatitis. Eur J Clin Invest. 2018;48(4):e12899. DOI:https://doi.org/10.1111/eci.12899.
- Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6(4):379–388. DOI:https://doi.org/10.1016/j.cgh.2007.12.048.
- Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020;72(2): 671–722. DOI:https://doi.org/10.1002/hep.31065.
- Jones D, Manns MP, Terracciano L, et al. Unmet needs and new models for future trials in autoimmune hepatitis. Lancet Gastroenterol Hepatol. 2018;3(5):363–370. DOI:https://doi.org/10.1016/S2468-1253(18)30043-8.
- Vierling JM, Kerkar N, Czaja AJ, et al. Immunosuppressive treatment regimens in autoimmune hepatitis: systematic reviews and meta-analyses supporting American Association for the Study of Liver Diseases guidelines. Hepatology. 2020;72(2): 753–769. DOI:https://doi.org/10.1002/hep.31407.
- Ambros V. microRNAs: tiny regulators with great potential. Cell. 2001;107(7):823–826.
- Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350–355.
- Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297. DOI:https://doi.org/10.1016/S0092-8674(04)00045-5.
- Kutter C, Svoboda P. miRNA, siRNA, piRNA: Knowns of the unknown. RNA Biol. 2008;5(4):181–188.
- Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–233. DOI:https://doi.org/10.1016/j.cell.2009.01.002.
- O’Brien J, Hayder H, Zayed Y, et al. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne). 2018;9:402. DOI:https://doi.org/10.3389/fendo.2018.00402.
- Hoefig KP, Heissmeyer V. MicroRNAs grow up in the immune system. Curr Opin Immunol. 2008;20(3):281–287.
- Liston A, Lu LF, O’Carroll D, et al. Dicer-dependent microRNA pathway safeguards regulatory T cell function. J Exp Med. 2008;205(9):1993–2004. DOI:https://doi.org/10.1084/jem.20081062.
- Zhou X, Jeker LT, Fife BT, et al. Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med. 2008;205(9):1983-91171–181. DOI:https://doi.org/10.1084/jem.20080707.
- Bi Y, Liu G, Yang R. MicroRNAs: novel regulators during the immune response. J Cell Physiol. 2009;218(3):467–472.
- Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun. 2009;32(3–4):189–194. DOI:https://doi.org/10.1016/j.jaut.2009.02.012.
- Kohlhaas S, Garden OA, Scudamore C, et al. Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells. J Immunol. 2009;182(5): 2578–2582. DOI:https://doi.org/10.4049/jimmunol.0803162.
- Yao R, Ma YL, Liang W, et al. MicroRNA-155 modulates Treg and Th17 cells differentiation and Th17 cell function by targeting SOCS1. PLoS One. 2012;7(10): e46082. DOI:https://doi.org/10.1371/journal.pone.0046082.
- Stanczyk J, Pedrioli DM, Brentano F, et al. Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum. 2008;58(4):1001–1009. DOI:https://doi.org/10.1002/art.23386.
- Nakasa T, Miyaki S, Okubo A, et al. Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum. 2008;58(5):1284–1292. DOI:https://doi.org/10.1002/art.23429.
- Pauley KM, Satoh M, Chan AL, et al. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther. 2008;10(4):R101. DOI:https://doi.org/10.1186/ar2493.
- Dai Y, Huang YS, Tang M, et al. Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus. 2007;16(12):939–946. DOI:https://doi.org/10.1177/0961203307084158.
- Dai Y, Sui W, Lan H, et al. Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol Int. 2009;29(7):749–754. DOI:https://doi.org/10.1007/s00296-008-0758-6.
- Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol. 2013;10(9):542–552. DOIhttps://doi.org/10.1038/nrgastro.2013.87.
- Takahashi K, Yan I, Wen HJ, et al. microRNAs in liver disease: from diagnostics to therapeutics. Clin Biochem. 2013;46(10–11): 946–952. DOI:https://doi.org/10.1016/j.clinbiochem.2013.01.025.
- Loosen SH, Schueller F, Trautwein C, et al. Role of circulating microRNAs in liver diseases. World J Hepatol. 2017;9(12): 586–594. DOI:https://doi.org/10.4254/wjh.v9.i12.586.
- Huang C, Xing X, Xiang X, et al. MicroRNAs in autoimmune liver diseases: from diagnosis to potential therapeutic targets. Biomed Pharmacother. 2020;130:110558. DOI:https://doi.org/10.1016/j.biopha.2020.110558.
- Yang Z, Zhang T, Kusumanchi P, et al. Transcriptomic analysis reveals the microRNAs responsible for liver regeneration associated with mortality in alcohol-associated hepatitis. Hepatology. 2021;74(5):2436–2451. DOI:https://doi.org/10.1002/hep-31994.
- Han S, Zhang T, Kusumanchi P, et al. Role of microRNA-7 in liver diseases: a comprehensive review of the mechanisms and therapeutic applications. J Investig Med. 2020;68(7):1208–1216. DOI:https://doi.org/10.1136/jim-2020-001420.
- Roderburg C, Urban GW, Bettermann K, et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology. 2011;53(1):209–218. DOI:https://doi.org/10.1002/hep.23922.
- Halasz T, Horvath G, Par G, et al. miR-122 negatively correlates with liver fibrosis as detected by histology and FibroScan. World J Gastroenterol. 2015;21(25): 7814–7823. DOI:https://doi.org/10.3748/wjg.v21.i25.7814.
- O’Reilly S. MicroRNAs in fibrosis: opportunities and challenges. Arthritis Res Ther. 2016;18(1):11.
- Appourchaux K, Dokmak S, Resche-Rigon M, et al. MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C. Sci Rep. 2016;6(1):34935. DOI:https://doi.org/10.1038/srep34935.
- El-Ahwany E, Nagy F, Zoheiry M, et al. Circulating miRNAs as predictor markers for activation of hepatic stellate cells and progression of HCV-induced liver fibrosis. Electron Physician. 2016;8(1):1804–1810. DOI:https://doi.org/10.19082/1804.
- Markovic J, Sharma AD, Balakrishnan A. MicroRNA-221: a fine tuner and potential biomarker of chronic liver injury. Cells. 2020;9(8):1767.
- Tadokoro T, Morishita A, Masaki T. Diagnosis and therapeutic management of liver fibrosis by microRNA. Int J Mol Sci. 2021;23(1):22.
- Wu H, Tao J, Li X, et al. MicroRNA-206 prevents the pathogenesis of hepatocellular carcinoma by modulating expression of met proto-oncogene and cyclin-dependent kinase 6 in mice. Hepatology. 2017;66(6):1952–1967. DOI:https://doi.org/10.1002/hep.29374.
- Li H, Zhou ZQ, Yang ZR, et al. MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma. Hepatology. 2017;66(1):136–151. DOI:https://doi.org/10.1002/hep.29116.
- Blaya D, Coll M, Rodrigo-Torres D, et al. Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation. Gut. 2016;65(9):1535–1545. DOI:https://doi.org/10.1136/gutjnl-2015-311314.
- Li M, He Y, Zhou Z, et al. MicroRNA-223 ameliorates alcoholic liver injury by inhibiting the IL-6-p47(phox)-oxidative IL-6–p47 phox –oxidative stress pathway in neutrophils. Gut. 2017;66(4):705–715. DOI:https://doi.org/10.1136/gutjnl-2016-311861.
- Yao J, Cheng Y, Zhang D, et al. Identification of key genes, MicroRNAs and potentially regulated pathways in alcoholic hepatitis by integrative analysis. Gene. 2019;720:144035.
- Pirola CJ, Fernandez Gianotti T, Castano GO, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015;64(5):800–812. DOI:https://doi.org/10.1136/gutjnl-2014-306996.
- Zhang T, Yang Z, Kusumanchi P, et al. Critical role of microRNA-21 in the pathogenesis of liver diseases. Front Med (Lausanne). 2020;7:7.
- Tan Y, Pan T, Ye Y, et al. Serum microRNAs as potential biomarkers of primary biliary cirrhosis. PLoS One. 2014;9(10): e111424. DOI:https://doi.org/10.1371/journal.pone.0111424.
- Itoh A, Adams D, Huang W, et al. Enoxacin up-regulates microRNA biogenesis and down-regulates cytotoxic CD8 T-cell function in autoimmune cholangitis. Hepatology. 2021;74(2): 835–846. DOI:https://doi.org/10.1002/hep.31724.
- Tu H, Chen D, Cai C, et al. microRNA-143-3p attenuated development of hepatic fibrosis in autoimmune hepatitis through regulation of TAK1 phosphorylation. J Cell Mol Med. 2020;24(2):1256-674394–4399. DOI:https://doi.org/10.1111/jcmm.14750.
- Czaja AJ. Emerging therapeutic biomarkers of autoimmune hepatitis and their impact on current and future management. Expert Rev Gastroenterol Hepatol. 2018;12(6):547–564. DOI:https://doi.org/10.1080/17474124.2018.1453356.
- Yamaura Y, Tatsumi N, Takagi S, et al. Serum microRNA profiles in patients with chronic hepatitis B, chronic hepatitis C, primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, or drug-induced liver injury. Clin Biochem. 2017;50(18):1034–1039. DOI:https://doi.org/10.1016/j.clinbiochem.2017.08.010.
- Wang X, He Y, Mackowiak B, et al. MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut. 2021;70(4):784–795. DOI:https://doi.org/10.1136/gutjnl-2020-322526.
- Migita K, Komori A, Kozuru H, et al. Circulating microRNA profiles in patients with type-1 autoimmune hepatitis. PLoS One. 2015;10(11): e0136908. DOI:https://doi.org/10.1371/journal.pone.0136908.
- Hutvagner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex. Science. 2002;297(5589):2056–2060.
- Rodriguez A, Griffiths-Jones S, Ashurst JL, et al. Identification of mammalian microRNA host genes and transcription units. Genome Res. 2004;14(10a):1902–1910. DOI:vhttps://doi.org/10.1101/gr.2722704.
- Haider BA, Baras AS, McCall MN, et al. A critical evaluation of microRNA biomarkers in non-neoplastic disease. PLoS One. 2014;9(2): e89565. DOI:https://doi.org/10.1371/journal.pone.0089565.
- Griffiths-Jones S. The microRNA Registry. Nucleic Acids Res. 2004;32(90001):D109–11.
- Griffiths-Jones S. miRBase: the microRNA sequence database. Methods Mol Biol. 2006;342:129–138.
- Griffiths-Jones S, Grocock RJ, van Dongen S, et al. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006;34(90001):D140–4. DOI:https://doi.org/10.1093/nar/gkj112.
- Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20.
- Hata A, Davis BN. Control of microRNA biogenesis by TGFbeta signaling pathway-A novel role of Smads in the nucleus. Cytokine Growth Factor Rev. 2009;20(5–6):517–521.
- Broderick JA, Zamore PD. MicroRNA therapeutics. Gene Ther. 2011;18(12):1104–1110. DOI:https://doi.org/10.1038/gt.2011.50.
- Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433(7027):769–773. DOI:https://doi.org/10.1038/nature03315.
- Lu LF, Gasteiger G, Yu IS, et al. A single miRNA-mRNA interaction affects the immune response in a context- and cell-type-specific manner. Immunity. 2015;43:52–64. DOI:https://doi.org/10.1016/j.immuni.2015.04.022.
- Erhard F, Haas J, Lieber D, et al. Widespread context dependency of microRNA-mediated regulation. Genome Res. 2014;24(6):906–919. DOI:https://doi.org/10.1101/gr.166702.113.
- McCall MN, Kent OA, Yu J, et al. MicroRNA profiling of diverse endothelial cell types. BMC Med Genomics. 2011;4(1):78. DOI:https://doi.org/10.1186/1755-8794-4-78.
- Laterza OF, Scott MG, Garrett-Engele PW, et al. Circulating miR-122 as a potential biomarker of liver disease. Biomark Med. 2013;7(2):205-106579–6606. DOI:https://doi.org/10.2217/bmm.12.107.
- Makarova JA, Shkurnikov MU, Wicklein D, et al. Intracellular and extracellular microRNA: An update on localization and biological role. Prog Histochem Cytochem. 2016;51(3–4):33–49. DOI:https://doi.org/10.1016/j.proghi.2016.06.001.
- O’Brien K, Breyne K, Ughetto S, et al. RNA delivery by extracellular vesicles in mammalian cells and its applications. Nat Rev Mol Cell Biol. 2020;21(10): 585–606. DOI:https://doi.org/10.1038/s41580-020-0251-y.
- Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478). DOI:https://doi.org/10.1126/science.aau6977
- Wang J, Chen J, Sen S. MicroRNA as biomarkers and diagnostics. J Cell Physiol. 2016;231(1):25–30.
- Leung AKL. The whereabouts of microRNA actions: cytoplasm and beyond. Trends Cell Biol. 2015;25(10):601–610. DOI:https://doi.org/10.1016/j.tcb.2015.07.005.
- Lagos-Quintana M, Rauhut R, Lendeckel W, et al. Identification of novel genes coding for small expressed RNAs. Science. 2001;294(5543):853–858. DOI:https://doi.org/10.1126/science.1064921.
- Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA. 2004;10(12):1957–1966.
- Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004;23(20):4051–4060. DOI:https://doi.org/10.1038/sj.emboj.7600385.
- Tomari Y, Zamore PD. Perspective: machines for RNAi. Genes Dev. 2005;19(5):517–529.
- Landthaler M, Yalcin A, Tuschl T. The human DiGeorge syndrome critical region gene 8 and Its D. melanogaster homolog are required for miRNA biogenesis. Curr Biol. 2004;14:2162–2167.
- Denli AM, Tops BB, Plasterk RH, et al. Processing of primary microRNAs by the Microprocessor complex. Nature. 2004;432(7014):231–235. DOI:https://doi.org/10.1038/nature03049.
- Han J, Lee Y, Yeom KH, et al. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 2004;18(24):3016–3027. DOI:https://doi.org/10.1101/gad.1262504.
- Gregory RI, Yan KP, Amuthan G, et al. The microprocessor complex mediates the genesis of microRNAs. Nature. 2004;432(7014):235–240. DOI:https://doi.org/10.1038/nature03120.
- Okada C, Yamashita E, Lee SJ, et al. A high-resolution structure of the pre-microRNA nuclear export machinery. Science. 2009;326(5957):1275–1279. DOI:https://doi.org/10.1126/science.1178705.
- Lund E, Guttinger S, Calado A, et al. Nuclear export of microRNA precursors. Science. 2004;303(5654):95–98. DOI:https://doi.org/10.1126/science.1090599.
- Zhang H, Kolb FA, Jaskiewicz L, et al. Single processing center models for human Dicer and bacterial RNase III. Cell. 2004;118(1):57–68. DOI:https://doi.org/10.1016/j.cell.2004.06.017.
- Pratt AJ, MacRae IJ. The RNA-induced silencing complex: a versatile gene-silencing machine. J Biol Chem. 2009;284(27):17897–17901. DOI:https://doi.org/10.1074/jbc.R900012200.
- Chendrimada TP, Gregory RI, Kumaraswamy E, et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature. 2005;436(7051):740–744. DOI:https://doi.org/10.1038/nature03868.
- Hutvagner G, Simard MJ. Argonaute proteins: key players in RNA silencing. Nat Rev Mol Cell Biol. 2008;9(1):22–32.
- Yoda M, Kawamata T, Paroo Z, et al. ATP-dependent human RISC assembly pathways. Nat Struct Mol Biol. 2010;17(1):17–23. DOI:https://doi.org/10.1038/nsmb.1733.
- Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell. 2003;115(2):209–216.
- Schwarz DS, Hutvagner G, Du T, et al. Asymmetry in the assembly of the RNAi enzyme complex. Cell. 2003;115(2):199–208. DOI:https://doi.org/10.1016/S0092-8674(03)00759-1.
- Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15(8):509–524.
- Ruby JG, Jan CH, Bartel DP. Intronic microRNA precursors that bypass Drosha processing. Nature. 2007;448(7149):83–86.
- Babiarz JE, Ruby JG, Wang Y, et al. Mouse ES cells express endogenous shRNAs, siRNAs, and other Microprocessor-independent, Dicer-dependent small RNAs. Genes Dev. 2008;22(20):2773–2785. DOI:https://doi.org/10.1101/gad.1705308.
- Cheloufi S, Dos Santos CO, Chong MM, et al. A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature. 2010;465(7298):584–589. DOI:https://doi.org/10.1038/nature09092.
- Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5’ UTR as in the 3’ UTR. Proc Natl Acad Sci U S A. 2007;104(23):9667–9672.
- Tolia NH, Joshua-Tor L. Slicer and the argonautes. Nat Chem Biol. 2007;3(1):36–43.
- Liu J, Carmell MA, Rivas FV, et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science. 2004;305(5689):1437–1441. DOI:https://doi.org/10.1126/science.1102513.
- Roberts TC. The microRNA biology of the mammalian nucleus. Mol Ther Nucleic Acids. 2014;3:e188.
- Matlin AJ, Clark F, Smith CW. Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol. 2005;6(5):386–398.
- Boulon S, Westman BJ, Hutten S, et al. The nucleolus under stress. Mol Cell. 2010;40(2):216–227. DOI:https://doi.org/10.1016/j.molcel.2010.09.024.
- Das S, Ferlito M, Kent OA, et al. Nuclear miRNA regulates the mitochondrial genome in the heart. Circ Res. 2012;110(12):1596–1603. DOI:https://doi.org/10.1161/CIRCRESAHA.112.267732.
- Sripada L, Tomar D, Prajapati P, et al. Systematic analysis of small RNAs associated with human mitochondria by deep sequencing: detailed analysis of mitochondrial associated miRNA. PLoS One. 2012;7(9):e44873. DOI:https://doi.org/10.1371/journal.pone.0044873.
- Jia HY, Chen F, Chen JZ, et al. MicroRNA expression profiles related to early stage murine concanavalin A-induced hepatitis. Cell Physiol Biochem. 2014;33(6):1933–1944. DOI:https://doi.org/10.1159/000362970.
- Shen WJ, Dong R, Chen G, et al. microRNA-222 modulates liver fibrosis in a murine model of biliary atresia. Biochem Biophys Res Commun. 2014;446(1):155–159. DOI:https://doi.org/10.1016/j.bbrc.2014.02.065.
- Lu Z, Liu J, Liu X, et al. MicroRNA 15a/16-1 suppresses aryl hydrocarbon receptor-dependent interleukin-22 secretion in CD4(+) CD4 + T cells and contributes to immune-mediated organ injury. Hepatology. 2018;67(3):1027–1040. DOI:https://doi.org/10.1002/hep.29573.
- Ke QH, Chen HY, He ZL, et al. Silencing of microRNA-375 affects immune function in mice with liver failure by upregulating astrocyte elevated gene-1 through reducing apoptosis of Kupffer cells. J Cell Biochem. 2019;120(1):253–263. DOI:https://doi.org/10.1002/jcb.27338.
- Wang YQ, Lan YY, Guo YC, et al. Down-regulation of microRNA-138 improves immunologic function via negatively targeting p53 by regulating liver macrophage in mice with acute liver failure. Biosci Rep. 2019;39(7). DOI:https://doi.org/10.1042/BSR20190763.
- Yang F, Lou G, Zhou X, et al. MicroRNA-223 acts as an important regulator to Kupffer cells activation at the early stage of Con A-induced acute liver failure via AIM2 signaling pathway. Cell Physiol Biochem. 2014;34(6):2137–2152. DOI:https://doi.org/10.1159/000369658.
- Su K, Wang Q, Qi L, et al MicroRNA-674-5p/5-LO axis involved in autoimmune reaction of Concanavalin A-induced acute mouse liver injury. Toxicol Lett. 2016;258:101–107.
- Blaya D, Aguilar-Bravo B, Hao F, et al. Expression of microRNA-155 in inflammatory cells modulates liver injury. Hepatology. 2018;68(2):691–706. DOI:https://doi.org/10.1002/hep.29833.
- Ruan Q, Wang P, Wang T, et al. MicroRNA-21 regulates T-cell apoptosis by directly targeting the tumor suppressor gene Tipe2. Cell Death Dis. 2014;5(2):e1095. DOI:https://doi.org/10.1038/cddis.2014.47.
- Sun H, Gong S, Carmody RJ, et al. TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell. 2008;133(3):415–426. DOI:https://doi.org/10.1016/j.cell.2008.03.026.
- Oho M, Nakano R, Nakayama R, et al. TIPE2 (tumor necrosis factor alpha-induced protein 8-like 2) is a novel negative regulator of TAK1 signal. J Biol Chem. 2016;291(43):22650–22660. DOI:https://doi.org/10.1074/jbc.M116.733451.
- Poria DK, Guha A, Nandi I, et al. RNA-binding protein HuR sequesters microRNA-21 to prevent translation repression of proinflammatory tumor suppressor gene programmed cell death 4. Oncogene. 2016;35(13):1703–1715. DOI:https://doi.org/10.1038/onc.2015.235.
- Lankat-Buttgereit B, Goke R. Programmed cell death protein 4 (pdcd4): a novel target for antineoplastic therapy?. Biol Cell. 2003;95(8):515–519.
- Hilliard A, Hilliard B, Zheng SJ, et al. Translational regulation of autoimmune inflammation and lymphoma genesis by programmed cell death 4. J Immunol. 2006;177(11):8095–8102. DOI:https://doi.org/10.4049/jimmunol.177.11.8095.
- Biyanee A, Ohnheiser J, Singh P, et al. A novel mechanism for the control of translation of specific mRNAs by tumor suppressor protein Pdcd4: inhibition of translation elongation. Oncogene. 2015;34(11):1384–1392. DOI:https://doi.org/10.1038/onc.2014.83.
- Ando Y, Yang GX, Kenny TP, et al. Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF-beta receptor type II mouse. J Autoimmun. 2013;41:111–119. DOI:https://doi.org/10.1016/j.jaut.2012.12.013.
- Iliopoulos D, Kavousanaki M, Ioannou M, et al. The negative costimulatory molecule PD-1 modulates the balance between immunity and tolerance via miR-21. Eur J Immunol. 2011;41(6):1754–1763. DOI:https://doi.org/10.1002/eji.201040646.
- Yao Q, Cao S, Li C, et al. Micro-RNA-21 regulates TGF-beta-induced myofibroblast differentiation by targeting PDCD4 in tumor-stroma interaction. Int J Cancer. 2011;128(8):1783–1792. DOI:https://doi.org/10.1002/ijc.25506.
- Huang C-KC-K, Kafert-Kasting S, Thum T. Preclinical and clinical development of noncoding RNA therapeutics for cardiovascular disease. Circ Res. 2020;126(5):663–678. DOI:https://doi.org/10.1161/CIRCRESAHA.119.315856.
- Karin M. How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene. 1999;18(49):6867–6874.
- Rouas R, Fayyad-Kazan H, El Zein N, et al. Human natural Treg microRNA signature: role of microRNA-31 and microRNA-21 in FOXP3 expression. Eur J Immunol. 2009;39(6):1608–1618. DOI:https://doi.org/10.1002/eji.200838509.
- Namdari H, Ghayedi M, Hadjati J, et al. Effect of microRNA-21 transfection on in-vitro differentiation of human naive CD4+ T cells to regulatory T cells. Iran J Allergy Asthma Immunol. 2017;16(3):235–244.
- Czaja AJ. Immune inhibitory properties and therapeutic prospects of transforming growth factor-beta and interleukin 10 in autoimmune hepatitis. Dig Dis Sci. 2022;67(4):1163–1186.
- Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity. 2000;12(2):171–181.
- Schramm C, Protschka M, Kohler HH, et al. Impairment of TGF-beta signaling in T cells increases susceptibility to experimental autoimmune hepatitis in mice. Am J Physiol Gastrointest Liver Physiol. 2003;284(3):G525–35. DOI:https://doi.org/10.1152/ajpgi.00286.2002.
- Sakaguchi K, Kitano M, Nishimura M, et al Serum level of transforming growth factor-beta 1 (TGF-beta 1) and the expression of TGF-beta receptor type II in peripheral blood mononuclear cells in patients with autoimmune hepatitis. Hepatogastroenterology. 2004;51(60):1780–1783.
- Chang J, Nicolas E, Marks D, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 2004;1(2):106–113. DOI:https://doi.org/10.4161/rna.1.2.1066.
- Jopling C. Liver-specific microRNA-122: Biogenesis and function. RNA Biol. 2012;9(2):137–142.
- Thakral S, Ghoshal K. miR-122 is a unique molecule with great potential in diagnosis, prognosis of liver disease, and therapy both as miRNA mimic and antimir. Curr Gene Ther. 2015;15(2):142–150. DOI:https://doi.org/10.2174/1566523214666141224095610.
- Satishchandran A, Ambade A, Rao S, et al. MicroRNA 122, regulated by GRLH2, protects livers of mice and patients from ethanol-induced liver disease. Gastroenterology. 2018;154(1):238–252. DOI:https://doi.org/10.1053/j.gastro.2017.09.022.
- Dubin PH, Yuan H, Devine RK, et al. Micro-RNA-122 levels in acute liver failure and chronic hepatitis C. J Med Virol. 2014;86(9):1507–1514. DOI:https://doi.org/10.1002/jmv.23987.
- Wang JH, Jiang D, Rao HY, et al Absolute quantification of serum microRNA-122 and its correlation with liver inflammation grade and serum alanine aminotransferase in chronic hepatitis C patients. Int J Infect Dis. 2015;30:52–56.
- Rissin DM, Lopez-Longarela B, Pernagallo S, et al. “Polymerase-free measurement of microRNA-122 with single base specificity using single molecule arrays: Detection of drug-induced liver injury.” PLoS One. 2017;12(7):e0179669. DOI:https://doi.org/10.1371/journal.pone.0179669.
- Liu Y, Li P, Liu L, et al. “The diagnostic role of miR-122 in drug-induced liver injury: A systematic review and meta-analysis.” Medicine (Baltimore). 2018;97(49):e13478. DOI:https://doi.org/10.1097/MD.0000000000013478.
- Hsu SH, Wang B, Kota J, et al., Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest. 2012;122(8): 2871–2883. DOI:https://doi.org/10.1172/JCI63539.
- Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006;3(2):87–98. DOI:https://doi.org/10.1016/j.cmet.2006.01.005.
- Chang J, Guo JT, Jiang D, et al. Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J Virol. 2008;82(16):8215–8223. DOI:https://doi.org/10.1128/JVI.02575-07.
- Sedano CD, Sarnow P. Hepatitis C virus subverts liver-specific miR-122 to protect the viral genome from exoribonuclease Xrn2. Cell Host Microbe. 2014;16(2):257–264.
- Miyaaki H, Ichikawa T, Kamo Y, et al. Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int. 2014;34(7):e302–7. DOI:https://doi.org/10.1111/liv.12429.
- Akuta N, Kawamura Y, Suzuki F, et al. Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma. BMC Gastroenterol. 2016;16(1):141. DOI:https://doi.org/10.1186/s12876-016-0557-6.
- Jopling CL, Yi M, Lancaster AM, et al. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science. 2005;309(5740):1577–1581. DOI:https://doi.org/10.1126/science.1113329.
- Jopling CL, Schutz S, Sarnow P. Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe. 2008;4(1):77–85.
- Doddapaneni R, Chawla YK, Das A, et al. Overexpression of microRNA-122 enhances in vitro hepatic differentiation of fetal liver-derived stem/progenitor cells. J Cell Biochem. 2013;114(7): 1575–1583. DOI:https://doi.org/10.1002/jcb.24499.
- Deng XG, Qiu RL, Wu YH, et al. Overexpression of miR-122 promotes the hepatic differentiation and maturation of mouse ESCs through a miR-122/FoxA1/HNF4a-positive feedback loop. Liver Int. 2014;34(2):281–295. DOI:https://doi.org/10.1111/liv.12239.
- Davoodian N, Lotfi AS, Soleimani M, et al. MicroRNA-122 overexpression promotes hepatic differentiation of human adipose tissue-derived stem cells. J Cell Biochem. 2014;115(9):1582–1593. DOI:https://doi.org/10.1002/jcb.24822.
- Copple BL, Bai S, Moon JO. Hypoxia-inducible factor-dependent production of profibrotic mediators by hypoxic Kupffer cells. Hepatol Res. 2010;40(5):530–539.
- Copple BL, Bai S, Burgoon LD, et al. Hypoxia-inducible factor-1alpha regulates the expression of genes in hypoxic hepatic stellate cells important for collagen deposition and angiogenesis. Liver Int. 2011;31(2):230–244. DOI:https://doi.org/10.1111/j.1478-3231.2010.02347.x.
- Nath B, Levin I, Csak T, et al. Hepatocyte-specific hypoxia-inducible factor-1 alpha is a determinant of lipid accumulation and liver injury in alcohol-induced steatosis in mice. Hepatology. 2011;53(5):1526–1537. DOI:https://doi.org/10.1002/hep.24256.
- Csak T, Bala S, Lippai D, et al. microRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis. Liver Int. 2015;35(2):532–541. DOI:https://doi.org/10.1111/liv.12633.
- Li J, Ghazwani M, Zhang Y, et al. miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. J Hepatol. 2013;58(3): 522–528. DOI:https://doi.org/10.1016/j.jhep.2012.11.011.
- Myllyharju J. Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis. Matrix Biol. 2003;22(1):15–24.
- Nath B, Szabo G. Hypoxia and hypoxia inducible factors: diverse roles in liver diseases. Hepatology. 2012;55(2):622–633.
- Ju C, Colgan SP, Eltzschig HK. Hypoxia-inducible factors as molecular targets for liver diseases. J Mol Med (Berl). 2016;94(6):613–627.
- Czaja AJ. Nature and implications of oxidative and nitrosative stresses in autoimmune hepatitis. Dig Dis Sci. 2016;61(10):2784–2803.
- Tanimizu N, Kobayashi S, Ichinohe N, et al. Downregulation of miR122 by grainyhead-like 2 restricts the hepatocytic differentiation potential of adult liver progenitor cells. Development. 2014;141(23):4448–4456. DOI:https://doi.org/10.1242/dev.113654.
- Wang B, Majumder S, Nuovo G, et al. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology. 2009;50(4):1152–1161. DOI:https://doi.org/10.1002/hep.23100.
- Yeligar S, Tsukamoto H, Kalra VK. Ethanol-induced expression of ET-1 and ET-BR in liver sinusoidal endothelial cells and human endothelial cells involves hypoxia-inducible factor-1alpha and microrNA-199. J Immunol. 2009;183(8):5232–5243.
- O’Connell RM, Taganov KD, Boldin MP, et al. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A. 2007;104(5):1604–1609. DOI:https://doi.org/10.1073/pnas.0610731104.
- Bala S, Marcos M, Kodys K, et al. Up-regulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor {alpha} (TNF{alpha}) production via increased mRNA half-life in alcoholic liver disease. J Biol Chem. 2011;286(2):1436–1444. DOI:https://doi.org/10.1074/jbc.M110.145870.
- Ruggiero T, Trabucchi M, De Santa F, et al. LPS induces KH-type splicing regulatory protein-dependent processing of microRNA-155 precursors in macrophages. FASEB J. 2009;23(9):2898–2908. DOI:https://doi.org/10.1096/fj.09-131342.
- Cheng YQ, Ren JP, Zhao J, et al. MicroRNA-155 regulates interferon-gamma interferon- γ production in natural killer cells via Tim-3 signalling in chronic hepatitis C virus infection. Immunology. 2015;145(4):485–497. DOI:https://doi.org/10.1111/imm.12463.
- Rodriguez A, Vigorito E, Clare S, et al. Requirement of bic/microRNA-155 for Normal Immune Function. Science. 2007;316(5824): 608–611. DOI:https://doi.org/10.1126/science.1139253.
- Vigorito E, Kohlhaas S, Lu D, et al. miR-155: an ancient regulator of the immune system. Immunol Rev. 2013;253(1):146–157. DOI:https://doi.org/10.1111/imr.12057.
- Seddiki N, Brezar V, Ruffin N, et al. Role of miR-155 in the regulation of lymphocyte immune function and disease. Immunology. 2014;142(1):32–38. DOI:https://doi.org/10.1111/imm.12227.
- Mashima R. Physiological roles of miR-155. Immunology. 2015;145(3):323–333.
- Pashangzadeh S, Motallebnezhad M, Vafashoar F, et al. Implications the role of miR-155 in the pathogenesis of autoimmune diseases. Front Immunol. 2021;12:669382. DOI:https://doi.org/10.3389/fimmu.2021.669382.
- Tam W. Identification and characterization of human BIC, a gene on chromosome 21 that encodes a noncoding RNA. Gene. 2001;274(1–2):157–167.
- Eis PS, Tam W, Sun L, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A. 2005;102(10):3627–3632. DOI:https://doi.org/10.1073/pnas.0500613102.
- Faraoni I, Antonetti FR, Cardone J, et al. miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta. 2009;1792(6):497–505. DOI:https://doi.org/10.1016/j.bbadis.2009.02.013.
- Thai TH, Calado DP, Casola S, et al. Regulation of the germinal center response by microRNA-155. Science. 2007;316(5824):604–608. DOI:https://doi.org/10.1126/science.1141229.
- Vigorito E, Perks KL, Abreu-Goodger C, et al. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity. 2007;27(6):847–859. DOI:https://doi.org/10.1016/j.immuni.2007.10.009.
- Ho IC, Lo D, Glimcher LH. c-maf promotes T helper cell type 2 (Th2) and attenuates Th1 differentiation by both interleukin 4-dependent and -independent mechanisms. J Exp Med. 1998;188(10):1859–1866.
- Lu LF, Thai TH, Calado DP, et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity. 2009;30(1): 80–91. DOI:https://doi.org/10.1016/j.immuni.2008.11.010.
- Xia G, Wu S, Wang X, et al. Inhibition of microRNA-155 attenuates concanavalin-A-induced autoimmune hepatitis by regulating Treg/Th17 cell differentiation. Can J Physiol Pharmacol. 2018;96(12):1293–1300. DOI:https://doi.org/10.1139/cjpp-2018-0467.
- Sporri B, Kovanen PE, Sasaki A, et al. JAB/SOCS1/SSI-1 is an interleukin-2-induced inhibitor of IL-2 signaling. Blood. 2001;97(1):221–226. DOI:https://doi.org/10.1182/blood.V97.1.221.
- Czaja AJ. Exploring the pathogenic role and therapeutic implications of interleukin 2 in autoimmune hepatitis. Dig Dis Sci. 2021;66(8):2493–2512.
- Kehrl JH, Muraguchi A, Goldsmith PK, et al. The direct effects of interleukin 1, interleukin 2, interferon-alpha, interferon-gamma, B-cell growth factor, and a B-cell differentiation factor on resting and activated human B cells. Cell Immunol. 1985;96(1):38–48. DOI:https://doi.org/10.1016/0008-8749(85)90338-7.
- Miyawaki T, Suzuki T, Butler JL, et al. Interleukin-2 effects on human B cells activated in vivo. J Clin Immunol. 1987;7(4):277–287. DOI:https://doi.org/10.1007/BF00915548.
- Arenas-Ramirez N, Woytschak J, Boyman O. Interleukin-2: biology, design and application. Trends Immunol. 2015;36(12):763–777.
- Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol. 2004;4(9):665–674.
- Antov A, Yang L, Vig M, et al. Essential Role for STAT5 Signaling in CD25+CD4+ CD25 + CD4 + Regulatory T Cell Homeostasis and the Maintenance of Self-Tolerance. J Immunol. 2003;171(7):3435–3441. DOI:https://doi.org/10.4049/jimmunol.171.7.3435.
- Zhan Y, Davey GM, Graham KL, et al. SOCS1 negatively regulates the production of Foxp3+ CD4+ Foxp3 + CD4 + T cells in the thymus. Immunol Cell Biol. 2009;87(6):473–480. DOI:https://doi.org/10.1038/icb.2009.23.
- Cao S, Liu J, Song L, et al. The protooncogene c-Maf is an essential transcription factor for IL-10 gene expression in macrophages. J Immunol. 2005;174(6):3484–3492. DOI:https://doi.org/10.4049/jimmunol.174.6.3484.
- Ho IC, Hodge MR, Rooney JW, et al. The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4. Cell. 1996;85(7):973–983. DOI:https://doi.org/10.1016/S0092-8674(00)81299-4.
- Hwang ES, White IA, Ho IC. An IL-4-independent and CD25-mediated function of c-maf in promoting the production of Th2 cytokines. Proc Natl Acad Sci U S A. 2002;99(20):13026–13030.
- Bauquet AT, Jin H, Paterson AM, et al. The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat Immunol. 2009;10(2):167–175. DOI:https://doi.org/10.1038/ni.1690.
- O’Connell RM, Chaudhuri AA, Rao DS, et al. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci U S A. 2009;106(17):7113–7118. DOI:https://doi.org/10.1073/pnas.0902636106.
- Locke NR, Patterson SJ, Hamilton MJ, et al. SHIP regulates the reciprocal development of T regulatory and Th17 cells. J Immunol. 2009;183(2): 975–983. DOI:https://doi.org/10.4049/jimmunol.0803749.
- Kurebayashi Y, Nagai S, Ikejiri A, et al. Recent advances in understanding the molecular mechanisms of the development and function of Th17 T h17 cells. Genes Cells. 2013;18(4):247–265. DOI:https://doi.org/10.1111/gtc.12039.
- Chen X, Guo Y, Han R, et al. Class I PI3K inhibitor ZSTK474 attenuates experimental autoimmune neuritis by decreasing the frequency of Th1/Th17 cells and reducing the production of proinflammatory cytokines. Cell Immunol. 2018;329:41–49.
- Chen S, Paveley R, Kraal L, et al. Selective targeting of PI3Kdelta suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases. J Autoimmun. 2020;111:102435.
- Wittrup A, Lieberman J. Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet. 2015;16:543–552
- Tagawa H, Ikeda S, Sawada K. Role of microRNA micro RNA in the pathogenesis of malignant lymphoma. Cancer Sci. 2013;104(7):801–809.
- Meister G, Landthaler M, Dorsett Y, et al. Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA. 2004;10(3):544–550. DOI:https://doi.org/10.1261/rna.5235104.
- Krutzfeldt J, Rajewsky N, Braich R, et al. “Silencing of microRNAs in vivo with antagomirs.” Nature. 2005;438(7068):685–689. DOI:https://doi.org/10.1038/nature04303.
- Krutzfeldt J, Kuwajima S, Braich R, et al. Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res. 2007;35(9):2885–2892. DOI:https://doi.org/10.1093/nar/gkm024.
- Duygu B, Juni R, Ottaviani L, et al. Comparison of different chemically modified inhibitors of miR-199b in vivo. Biochem Pharmacol. 2019;159:106–115.
- Petersen M, Wengel J. LNA: a versatile tool for therapeutics and genomics. Trends Biotechnol. 2003;21(2):74–81.
- Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature. 2008;452(7189):896–899. DOI:https://doi.org/10.1038/nature06783.
- Bernardo BC, Ooi JY, Lin RC, et al. miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart. Future Med Chem. 2015;7(13):1771–1792. DOI:https://doi.org/10.4155/fmc.15.107.
- Gomez IG, MacKenna DA, Johnson BG, et al. Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J Clin Invest. 2015;125(1):141–156. DOI:https://doi.org/10.1172/JCI75852.
- Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368(18):1685–1694. DOI:https://doi.org/10.1056/NEJMoa1209026.
- Gebert LF, Rebhan MA, Crivelli SE, et al. Miravirsen (SPC3649) can inhibit the biogenesis of miR-122. Nucleic Acids Res. 2014;42(1):609–621. DOI:https://doi.org/10.1093/nar/gkt852.
- van der Ree MH, de Vree JM, Stelma F, et al. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial. Lancet. 2017;389(10070):709–717. DOI:https://doi.org/10.1016/S0140-6736(16)31715-9.
- Anastasiadou E, Seto AG, Beatty X, et al. Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo. Clin Cancer Res. 2021;27(4):1139–1149. DOI:https://doi.org/10.1158/1078-0432.CCR-20-3139.
- Huang L, Jin J, Deighan P, et al. Efficient and specific gene knockdown by small interfering RNAs produced in bacteria. Nat Biotechnol. 2013;31(4):350–356. DOI:https://doi.org/10.1038/nbt.2537.
- Franco-Zorrilla JM, Valli A, Todesco M, et al. Target mimicry provides a new mechanism for regulation of microRNA activity. Nat Genet. 2007;39(8):1033–1037. DOI:https://doi.org/10.1038/ng2079.
- Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods. 2007;4(9):721–726.
- Haraguchi T, Ozaki Y, Iba H. Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res. 2009;37(6):e43.
- Shan G, Li Y, Zhang J, et al. A small molecule enhances RNA interference and promotes microRNA processing. Nat Biotechnol. 2008;26(8):933–940. DOI:https://doi.org/10.1038/nbt.1481.
- Melo S, Villanueva A, Moutinho C, et al. Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci U S A. 2011;108(11):4394–4399. DOI:https://doi.org/10.1073/pnas.1014720108.
- Cruz-Guilloty F, Pipkin ME, Djuretic IM, et al. Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. J Exp Med. 2009;206(1):51–59. DOI:https://doi.org/10.1084/jem.2008/1242.
- Wang X, Wen X, Zhou J, et al. MicroRNA-223 and microRNA-21 in peripheral blood B cells associated with progression of primary biliary cholangitis patients. PLoS One. 2017;12:e0184292.
- Rossi L, Bonmassar E, Faraoni I. Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro. Pharmacol Res. 2007;56(3):248–253.
- Song E, Lee SK, Wang J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med. 2003;9(3): 347–351. DOI:https://doi.org/10.1038/nm828.
- Blower PE, Verducci JS, Lin S, et al. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther. 2007;6(5):1483–1491. DOI:https://doi.org/10.1158/1535-7163.MCT-07-0009.
- Liu CG, Calin GA, Meloon B, et al. An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci U S A. 2004;101(26):9740–9744. DOI:https://doi.org/10.1073/pnas.0403293101.
- Gaur A, Jewell DA, Liang Y, et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 2007;67(6):2456–2468. DOI:https://doi.org/10.1158/0008-5472.CAN-06-2698.